Could an arthritis drug help the brain heal after a stroke?
NCT ID NCT06737705
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether baricitinib, an anti-inflammatory drug, can improve neurological outcomes in people who have had a spontaneous intracerebral hemorrhage (a type of stroke caused by bleeding in the brain). About 110 adults in China will receive either baricitinib plus standard care or standard care alone for 14 days. The study measures recovery using the modified Rankin Scale, which assesses disability after stroke.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
baricitinib
What this could lead to
If it works, this could point toward a new treatment to improve recovery after a brain bleed.
What could go wrong
This is an early phase 2 trial with only 110 participants, so results may not apply to everyone. Baricitinib can suppress the immune system, raising infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRACEREBRAL HEMORRHAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, 350003, China
-
First Affiliated Hospital of Gannan Medical University
Ganzhou, Jiangxi, 341000, China
-
Ganzhou People's Hospital
Ganzhou, Jiangxi, 341000, China
-
Liaocheng People's Hospital, Liaocheng Brain Hospital
Liaocheng, Shandong, China
-
The Southwest Hospital of Army Medical University
Chongqing, Chongqing Municipality, 400038, China
-
Tianjin Huanhu Hospital
Tianjin, Tianjin Municipality, China